Question 10: Were there any topics (scientific or otherwise) that were not addressed at this meeting that you would like to see at future ASPET meetings?

Attendee Responses:

- Artificial intelligence (AI) and its applications in pharmacology research, drug discovery, and education
- Non-animal models and AI
- Endocrine pharmacology (diabetes, obesity, fatty liver, thyroid)
- Endocrinology or reproductive/developmental biology
- Government or military lab research, exposure of diverse government fellowship opportunities for young trainees (NRC Research Associateship, AEOP Fellowships, etc.)
- Engaging with government labs doing pharmacology research, FDA approval of novel compounds
- Immunopharmacology
- Immunology
- Pharmacology education
- PK and PD studies for new therapeutic modalities such as PROTACs
- Session on the study of pharmacology (pharmacokinetics and pharmacodynamics) in understudied ethnic populations.
- PKPD modeling work
- Environmental toxicology
- Drug-induced liver toxicity
- Platelet biology, thrombotic disorders
- Safety pharmacology
- Classical pharmacology, drug metabolism and transport sessions
- Neurodegenerative diseases, and nervous system diseases / treatments in general
- How to do different rat or mice models of diseases to teach young scientists. Also how to prepare efficient Pharmacology Curriculum and question banks.
- Renin angiotensin system
- Epigenetic
- PhD / MS program-oriented content - program director activities
- Lifestyle related pharmacology
• More diversity and sessions like the "non-significant data" session
• A session in which participants who have completed at least five years of their journey with ASPET share their success stories and how ASPET played an important role in shaping their careers. The ASPET committee can select one member from each division, and the selected participants can give a 10-minute elevator talk. I hope this kind of session will be more inspiring for new members and those who are attending their first ASPET meeting.
• Cancer Pharmacology and Molecular Pharmacology sessions with PI level talks.
• More emphasis in translational science
• Less purely translational research, more emphasis on fundamental research
• Cancer-related topics
• More information about transitioning to work in industry and hear some people from industry talk. Also, the moral obligations of people who work in pharmaceutical development.
• GPCR
• More generalized topics that are of interest to a wide array of people
• Emerging pharmacologic targets
• Adipose tissue and obesity
• GLP-1 content
• Pharmacogenomics
• Opioids
• Nuclear receptors and new therapeutic/vaccination modalities
• Drug discovery especially in the field of targeted protein degradation
• Mitochondria function and muscle atrophy
• More focus on the RAS
• Biologics
• More interdisciplinary integrative and collaborative programming
• More discussion about the adverse impact of bias in science
• The results of the poll at Holden Thorp's talk was terrifying. ASPET has the chance to pioneer the movement for scientists to be advocates before it is too late for society. Would love to see more high-level summaries of the different fields instead of deep details.
• Professional development for non-trainees
• It would be great to have a larger industry presence.
• Pharmacology industry development
• Plant based pharmacology. Low efficacy polypharmacy
• Cellular and biological therapy
• A few sessions devoted to "fringe" ideas could be great for stimulating discussions